Effects of ipratropium bromide in treatment of chronic obstructive pulmonary asthma syndrome and its effect on sputum VEGF, ICAM-1, IL-13 and IL-17 QIN Biyuan
QIN Biyuan
ZENG Chunfang
WANG Xiao
ZENG Jianming
FENG Yinhe
Abstract：Objective To study the effect of ipratropium bromide in the treatment of chronic obstructive pulmonary asthma syndrome and the effect of sputum vascular endothelial growth factor (VEGF), intercellular adhesion molecule (ICAM-1), interleukin 13 (IL-13), IL-17.Methods From March 2015 to February 2016, 84 patients with chronic obstructive pulmonary asthma syndrome were enrolled from department of respiratory medicine, Deyang people's hospital of Sichuan province hospital.According to the order of admission, the patients were divided into observation group and control group, 42 cases in each group.The control group was treated with conventional treatment combination of budesonide dermotam powder inhalation, and the observation group was treated with ipratropium bromide on the basis of the control group.The clinical effects, levels of VEGF, ICAM-1, IL-13, IL-17, lung function and adverse effects were compared between the two groups.Results After treatment, the total effective rate of the observation group was significantly higher than that of the control group[92.86% vs.73.81%,χ2=5.485, P =0.019].The levels of VEGF, ICAM-1, IL-13 and IL-17 in the sputum of the observation group were significantly lower than those in the control group[(56.32±5.15)ng/L,(101.34±9.43)μg/L,(66.21±6.24)ng/L,(16.98±1.43)ng/L vs.(78.98±7.23) ng/L,(135.21±14.52)μg/L,(87.59±8.24)ng/L,(32.13±3.45)ng/L, t =16.544, t =12.678, t =13.405, t =26.290, P =0.000, P =0.000, P =0.000, P =0.000].The observation group with vital capacity (FVC), the percentage of forced respiration volume (FEV1%), the maximum expiratory flow (MMEF) and the peak expiratory flow velocity (PEF) were higher than those in the control group[(3.32±0.37) L, (74.21±7.43)%, (169.18±18.76) L/min, (253.32±23.65) L/min vs.(2.53±0.27) L, (63.76±6.21)%, (131.43±13.76) L/min, (181.56±18.43) L/min, t =11.178, t =6.994, t =10.516, t =15.511, P =0.000, P =0.000, P =0.000, P =0.000].There was no significant difference in the adverse reaction rate between the two groups (26.19% vs 23.81%,χ2=0.064, P >0.05).Conclusion Ipratropium bromide in patients with chronic obstructive pulmonary asthma overlap syndrome, which can decrease the levels of VEGF, ICAM-1, IL-13 and IL-17, which can improve the pulmonary ventilation function of patients with good clinical efficacy and high safety.
Keywords：Ipratropium bromideChronic obstructive pulmonary asthma syndromeVascular endothelial growth factorIntercellular adhesion moleculeInterleukin 13Interleukin 17
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 885-888 )